Safety profile of tranexamic acid during and after caesarean section
Abstract
Introduction: Delivery by caesarean section can cause many complications. The most common complications documented are primary and secondary postpartum hemorrhage. Tranexamic acid is a synthetic analogue of the amino acid lysine and its action is to reduce blood loss. Both antepartum and PPH are being treated by TXA extensively. The present study was undertaken to evaluate the efficacy and safety of tranexamic acid in reducing the blood loss during and after LSCS.
Material & Methods: Hundred pregnant women undergoing LSCS were included in the study. Subject were allocated in two groups–1) Study group–50 Subject who received tranexamic acid. 2) Control group–50 Subject who did not received tranexamic acid.
Results: There was no significant alteration in the vital signs of subjects following tranexamic acid administration at time of delivery & at 1 hr & 2 hr postpartum. In our study, not a single patient developed signs of thrombosis. The side effects of tranexamic acid as nausea, vomiting & diarrhea were not statistically significant in both the groups in our study. In our study, there was no statistical difference in APGAR score at 1 & 5 minutes of the baby in both the groups.
Conclusion: Data analysis of our study suggests that tranexamic acid can be used safely in LSCS with no serious side effects, and without increasing the occurrence of thrombosis.
Downloads
References
Kambo I, Bedi N, Dhillon BS, Saxena NC. A critical appraisal of cesarean section rates at teaching hospitals in India. Int J Gynaecol Obstet. 2002 Nov;79(2):151-8.
Tidsskr Nor Taegeforen: Hemmorhage in LSCS; J Obstet Gynaecol Oct 10 (2000) 120(24) 2864-6.
Thorsen S. Differences in the binding to fibrin of native plasminogen modified by proteolytic degradation: influence of w- aminocaproic acids. Biochem Biophys Acta 1975; 393:55-65.
Hoylaerts M, Linjen HR, Colleen D: Studies on mechanism of antifibrinolytic action of tranexamic acid. Biochem Biophys Acta 1981; 673:75-85.
Rydin E, Lundberg PO:Tranexamic acid and intracranial thrombosis. Lancet. 1976 Jul 3;2(7975):49–49.
Albronda T, Gokemeyer JD, van Haeflen TW:Transient acute renal failure due to tranexaminic acid therapy for diffuse intravascular coagulation. Neth J Med. 1991 Aug;39(1-2):127-8.
Fernandez Lucas M, Liano F, Navarro JF, Sastre JL, Quereda C, Ortuno J. Acute renal failure secondary to antifibrinolytic therapy. Nephron. 1995;69(4):478-9.
Ekvarn S. Summary and evaluation of toxicological data. Stockholm, Sweden: Data on file, KabiVitrum AB; 198.
Theil PL. Ophthalmological examination of patients in long-term treatment with tranexamic acid. Acta Ophthalmol (Copenh). 1981 Apr;59(2):237-41.
Pharmacia. Cyklokapron. ABPI Compendium of data sheets and summaries of product characteristics. London: Data pharm Publications Ltd.; 1998-99.
Robblee. Graft Occlusion Following administration of Tranexamic Acid. Anesth Analg. 1995 April;80:Suppl: SCA141.
Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy & the risk of thromboembolic complications. Throm Haemost 1993 Aug 2; 70:238-40.
Miya-ying Gai, Lian-fang Wu, Qi-fengs Su: Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial (Eur J Obstet Gynecol Reprod Biol, 2004;112:154–7).
Zheng SR, Yang HX, et al. Clinical study on the efficacy of tranexamic acid in reducing postpartum blood loss. Chin J Obstet Gynecol 2001; 36:59.
Bresnoc, et al. Tranexamic acid in postpartum hemmorhage. Bre J Obstet Gynecol 1996 Dec. 102(12):1250-1.
Gohel M, Purvi P, Ashoo G, Pankaj D et al Efficacy of tranexamic acid in reducing blood loss during and after the lower segment cesarean section.: A randomized case controlled prospective study.( Obstet Gynecol India.2007 ;50. (3) ;228-230 ).
Ker K, Edwards P, Perel P, Shakur H, Roberts I: Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012; 344: e3054. doi: https://doi.org/10.1136/bmj.e3054.
Perel P, Ker K, Morales Uribe CH, Roberts I: Tranexamic acid for re¬ducing mortality in emergency and urgent surgery. Cochrane database Syst Rev 2013; 1: CD010245. doi: https://doi.org/10.1002/14651858.CD010245.pub2.
Shakur, H., Roberts, I., Bautista, R. et al, CRASH-2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial.Lancet Elsevier Ltd 2010; 376: 23–32.
Tzortzopoulou A, Cepeda MS, Schumann R, Carr DB: Antifibri¬nolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane database Syst Rev 2008; 3: CD006883. doi: https://doi.org/10.1002/14651858.CD006883.pub2.
Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W: Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res 2009; 123: 687–696. doi: https://doi.org/10.1016/j.thromres.2008.09.015.
Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011 Jan;93(1):39-46. doi: https://doi.org/10.1302/0301-620X.93B1.24984.
Alshryda S, Sarda P, Sukeik M, Nargol a, Blenkinsopp J, Mason JM: Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br 2011; 93: 1577–1585. doi: https://doi.org/10.1302/0301-620X.93B12.26989.
Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV: Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis. Knee 2013; 20: 300–309. doi: https://doi.org/10.1016/j.knee.2013.05.014.
Fergusson DA, Hébert PC, Mazer CD et al.: A comparison of apro¬tinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319–2331. doi: https://doi.org/10.1056/NEJMoa0802395.
Ngaage DL, Bland JM: Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies. Eur J Cardio-thoracic Surg 2010; 37: 1375–1383. doi: https://doi.org/10.1016/j.ejcts.2009.11.055.
Adler Ma SC, Brindle W, Burton G, Gallacher S, Hong FC, Manelius I, Smith A, Ho W, Alston RP, Bhattacharya K.Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis..J Cardiothorac Vasc Anesth. 2011 Feb;25(1):26-35. doi: https://doi.org/10.1053/j.jvca.2010.08.012. Epub 2010 Nov 5.
Lethaby A, Farquhar C, Cooke I: Antifibrinolytics for heavy menstrual bleeding. Cochrane database Syst Rev 2000; 4: CD000249.
Lukes AS, Moore KA, Muse KN et al.: Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116: 865–875. doi: https://doi.org/10.1097/AOG.0b013e3181f20177.
Gohel M, Patel P, Gupta A, Desai P: Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: A randomized case controlled prospective study. J Obstet Gynecol India Vol. 57, No. 3 : May/June 2007 Pg 227-230.
Ducloy-Bouthors A-S, Jude B, Duhamel A et al.: High-dose trane¬xamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011; 15: R117. doi: https://doi.org/10.1186/cc10143.
Ferrer P, Roberts I, Sydenham E, Blackhall K, Shakur H. Anti-fibrinolytic agents in post partum haemorrhage: A systematic review. BMC Pregnancy Childbirth 2009;9:29.
Astedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroenterol Suppl 1987;137:22-5.
Bhatia SK, Deshpande H. Role of tranexamic acid in reducing blood loss during and after caesarean section. Med J DY Patil Univ 2015;8:21-5. DOI: http://www.mjdrdypu.org/text.asp?2015/8/1/21/148830.
OAI - Open Archives Initiative
